Long Term Effects of Using Medicinal Mushroom Preparations in Human Colorectal and Breast Cancer

Long Term Effects of Using Medicinal Mushroom Preparations in Human Colorectal and Breast Cancer

This conference presentation summarizes long-term observational results on the use of multi-species medicinal mushroom extracts (mycotherapy) as adjuvant and primary supportive therapy in patients with colorectal and breast cancer.
The analysis covers a consecutive cohort of 141 patients (52 colorectal, 89 breast cancer) treated between 2005 and 2006, with follow-up through 2010. Clinical outcomes were evaluated using official medical records and cancer registries.
Key findings include:
•    High short-term regression rates in both cancer types (≈50% in colorectal and ≈42% in breast cancer) compared to very low regression under standard chemotherapy alone (4% and 1.5%).
•    Metastasis reduction of approximately 20% in both groups, without hepatotoxicity or other major adverse effects.
•    Significant survival improvements, especially in Stage 4 colorectal cancer, where 5-year survival reached 26.5%, compared to the official 5–8% expected rate.
•    Dose-dependent patterns, with higher cumulative intake of mushroom extracts generally associated with improved regression and longer survival, particularly in colorectal cancer.
Overall, the results suggest that properly dozed medicinal mushroom preparations may offer meaningful supportive benefits in oncology care, improving regression rates, metastatic control, and long-term survival without added toxicity.